Evolutionary and pulsational properties of white dwarf stars

Abridged. White dwarf stars are the final evolutionary stage of the vast majority of stars, including our Sun. The study of white dwarfs has potential applications to different fields of astrophysics. In particular, they can be used as independent reliable cosmic clocks, and can also provide valuable information about the fundamental parameters of a wide variety of stellar populations, like our Galaxy and open and globular clusters. In addition, the high densities and temperatures characterizing white dwarfs allow to use these stars as cosmic laboratories for studying physical processes under extreme conditions that cannot be achieved in terrestrial laboratories. They can be used to constrain fundamental properties of elementary particles such as axions and neutrinos, and to study problems related to the variation of fundamental constants. In this work, we review the essentials of the physics of white dwarf stars. Special emphasis is placed on the physical processes that lead to the formation of white dwarfs as well as on the different energy sources and processes responsible for chemical abundance changes that occur along their evolution. Moreover, in the course of their lives, white dwarfs cross different pulsational instability strips. The existence of these instability strips provides astronomers with an unique opportunity to peer into their internal structure that would otherwise remain hidden from observers. We will show that this allows to measure with unprecedented precision the stellar masses and to infer their envelope thicknesses, to probe the core chemical stratification, and to detect rotation rates and magnetic fields. Consequently, in this work, we also review the pulsational properties of white dwarfs and the most recent applications of white dwarf asteroseismology.Comment: 85 pages, 28 figures. To be published in The Astronomy and Astrophysics Revie

Honey bee colony winter loss rates for 35 countries participating in the COLOSS survey for winter 2018–2019, and the effects of a new queen on the risk of colony winter loss

peer-reviewedThis article presents managed honey bee colony loss rates over winter 2018/19 resulting from using the standardised COLOSS questionnaire in 35 countries (31 in Europe). In total, 28,629 beekeepers supplying valid loss data wintered 738,233 colonies, and reported 29,912 (4.1%, 95% confidence interval (CI) 4.0–4.1%) colonies with unsolvable queen problems 79,146 (10.7%, 95% CI 10.5–10.9%) dead colonies after winter and 13,895 colonies (1.9%, 95% CI 1.8–2.0%) lost through natural disaster. This gave an overall colony winter loss rate of 16.7% (95% CI 16.4–16.9%), varying greatly between countries, from 5.8% to 32. 0%. We modelled the risk of loss as a dead/empty colony or from unresolvable queen problems and found that, overall, larger beekeeping operations with more than 150 colonies experienced significantly lower losses (p<0.001), consistent with earlier studies. Additionally, beekeepers included in this survey who did not migrate their colonies at least once in 2018 had significantly lower losses than those migrating (p<0.001). The percentage of new queens from 2018 in wintered colonies was also examined as a potential risk factor. The percentage of colonies going into winter with a new queen was estimated as 55.0% over all countries. Higher percentages of young queens corresponded to lower overall losses (excluding losses from natural disaster), but also lower losses from unresolvable queen problems, and lower losses from winter mortality (p<0.001). Detailed results for each country and overall are given in a table, and a map shows relative risks of winter loss at regional level

Pulsating White Dwarf Stars and Precision Asteroseismology

Galactic history is written in the white dwarf stars. Their surface properties hint at interiors composed of matter under extreme conditions. In the forty years since their discovery, pulsating white dwarf stars have moved from side-show curiosities to center stage as important tools for unraveling the deep mysteries of the Universe. Innovative observational techniques and theoretical modeling tools have breathed life into precision asteroseismology. We are just learning to use this powerful tool, confronting theoretical models with observed frequencies and their time rate-of-change. With this tool, we calibrate white dwarf cosmochronology; we explore equations of state; we measure stellar masses, rotation rates, and nuclear reaction rates; we explore the physics of interior crystallization; we study the structure of the progenitors of Type Ia supernovae, and we test models of dark matter. The white dwarf pulsations are at once the heartbeat of galactic history and a window into unexplored and exotic physics.Comment: 70 pages, 11 figures, to be published in Annual Review of Astronomy and Astrophysics 200

Supplementary information for the article: Brodschneider, R.; Schlagbauer, J.; Arakelyan, I.; Ballis, A.; Brus, J.; Brusbardis, V.; Cadahía, L.; Charrière, J.-D.; Chlebo, R.; Coffey, M. F.; Cornelissen, B.; da Costa, C. A.; Danneels, E.; Danihlík, J.; Dobrescu, C.; Evans, G.; Fedoriak, M.; Forsythe, I.; Gregorc, A.; Johannesen, J.; Kauko, L.; Kristiansen, P.; Martikkala, M.; Martín-Hernández, R.; Mazur, E.; Mutinelli, F.; Patalano, S.; Raudmets, A.; Simon Delso, N.; Stevanovic, J.; Uzunov, A.; Vejsnæs, F.; Williams, A.; Gray, A. Spatial Clusters of Varroa Destructor Control Strategies in Europe. J Pest Sci 2022. https://doi.org/10.1007/s10340-022-01523-2.

Table S1. Utilized packages of the statistical software R version 4.0.4.Supplementary material for: [https://vet-erinar.vet.bg.ac.rs/handle/123456789/2469]Related to the published version: [https://vet-erinar.vet.bg.ac.rs/handle/123456789/2469

Spatial clusters of Varroa destructor control strategies in Europe

Publication history: Accepted - 18 May 2022; Published online - 29 June 2022Beekeepers have various options to control the parasitic mite Varroa destructor in honey bee colonies, but no empirical data are available on the methods they apply in practice. We surveyed 28,409 beekeepers maintaining 507,641 colonies in 30 European countries concerning Varroa control methods. The set of 19 diferent Varroa diagnosis and control measures was taken from the annual COLOSS questionnaire on honey bee colony losses. The most frequent activities were monitoring of Varroa infestations, drone brood removal, various oxalic acid applications and formic acid applications. Correspondence analysis and hierarchical clustering on principal components showed that six Varroa control options (not necessarily the most used ones) signifcantly contribute to defning three distinctive clusters of countries in terms of Varroa control in Europe. Cluster I (eight Western European countries) is characterized by use of amitraz strips. Cluster II comprises 15 countries from Scandinavia, the Baltics, and Central-Southern Europe. This cluster is characterized by long-term formic acid treatments. Cluster III is characterized by dominant usage of amitraz fumigation and formed by seven Eastern European countries. The median number of diferent treatments applied per beekeeper was lowest in cluster III. Based on estimation of colony numbers in included countries, we extrapolated the proportions of colonies treated with diferent methods in Europe. This suggests that circa 62% of colonies in Europe are treated with amitraz, followed by oxalic acid for the next largest percentage of colonies. We discuss possible factors determining the choice of Varroa control measures in the diferent clustersOpen access funding provided by University of Graz. The authors have no relevant financial or non-financial interests to disclose. COLOSS and its supporters had no influence on the study design or the decision to publish

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

BACKGROUND: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. PATIENTS AND METHODS: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8\u2009mg/kg loading dose, then 6\u2009mg/kg every 3\u2009weeks (q3w)] and pertuzumab (840\u2009mg loading dose, then 420\u2009mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). RESULTS: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54\u2009years; 29% had received prior trastuzumab. Median treatment duration was 16\u2009months for pertuzumab and trastuzumab and 4\u2009months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1\u2009months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. CLINICALTRIALS.GOV: NCT01572038

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Honey bee colony loss rates in 37 countries using the COLOSS survey for winter 2019–2020: the combined effects of operation size, migration and queen replacement

Publication history: Accepted - 12 July 2022; Published online - 6 September 2022.This article presents managed honey bee colony loss rates over winter 2019/20 resulting from using the standardised COLOSS questionnaire in 37 countries. Six countries were from outside Europe, including, for the first time in this series of articles, New Zealand. The 30,491 beekeepers outside New Zealand reported 4.5% of colonies with unsolvable queen problems, 11.1% of colonies dead after winter and 2.6% lost through natural disaster. This gave an overall colony winter loss rate of 18.1%, higher than in the previous year. The winter loss rates varied greatly between countries, from 7.4% to 36.5%. 3216 beekeepers from New Zealand managing 297,345 colonies reported 10.5% losses for their 2019 winter (six months earlier than for other, Northern Hemisphere, countries). We modelled the risk of loss as a dead/empty colony or from unresolvable queen problems, for all countries except New Zealand. Overall, larger beekeeping operations with more than 50 colonies experienced significantly lower losses (p<0.001). Migration was also highly significant (p<0.001), with lower loss rates for operations migrating their colonies in the previous season. A higher proportion of new queens reduced the risk of colony winter loss (p<0.001), suggesting that more queen replacement is better. All three factors, operation size, migration and proportion of young queens, were also included in a multivariable main effects quasi-binomial GLM and all three remained highly significant (p<0.001). Detailed results for each country and overall are given in a table, and a map shows relative risks of winter loss at the regional level.Dutch Ministry of Agriculture, Nature and Food Quality (BO-43-011.03-005); Republic of Serbia, MPNTR-RS, through Grant No. III46002; Slovakia the project "Sustainable smart farming systems taking into account the future challenges 313011W112"; Slovenian Research Program P1-0164; Danish Beekeepers Association for their funding and support of the international LimeSurvey platform used by many participating countries; “Zukunft Biene 2” (grant number 101295/2) in Austria; University of Graz for open access